Tadliq (Tadalafil) Patent Expiration, LOE Window & CMS Spending

Tadliq (Tadalafil) by Cmp Development: FDA Orange Book LOE 2038-12-24, 39 AB generics, $8.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCmp Development
FDA Application & PathwayN214522 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-12-24
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors39
2024 CMS Total Public Spend$8.8M
2024 Medicare Part D Spend$174K
2024 Medicaid Spend$8.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel